Patents by Inventor Steve DOWER

Steve DOWER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Truncated von Willebrand Factor polypeptides for treating hemophilia
    Patent number: 11814421
    Abstract: The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 14, 2023
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Stefan Schulte, Thomas Weimer, Sabine Pestel, Hubert Metzner, Steve Dower
  • Mutated truncated von Willebrand Factor
    Patent number: 10806774
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 20, 2020
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Arna Andrews, Con Panousis, Kerstin Emmrich, Michael Wilson, Steve Dower, Matthew Hardy, Dallas Hartman
  • Mutated von Willebrand factor
    Patent number: 10808023
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 20, 2020
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Arna Andrews, Con Panousis, Kerstin Emmrich, Michael Wilson, Steve Dower, Matthew Hardy, Dallas Hartman
  • TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR TREATING HEMOPHILIA
    Publication number: 20190263890
    Abstract: The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 29, 2019
    Inventors: Stefan SCHULTE, Thomas WEIMER, Sabine PESTEL, Hubert METZNER, Steve DOWER
  • Modified von Willebrand Factor
    Patent number: 10253088
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to Factor VIII with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 9, 2019
    Assignee: CSL Behring Lengnau AG
    Inventors: Michael Wilson, Steve Dower, Dallas Hartman, Mathew Hardy
  • MUTATED VON WILLEBRAND FACTOR
    Publication number: 20190016784
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Inventors: Arna ANDREWS, Con PANOUSIS, Kerstin EMMRICH, Michael WILSON, Steve DOWER, Matthew HARDY, Dallas HARTMAN
  • MUTATED TRUNCATED VON WILLEBRAND FACTOR
    Publication number: 20190015483
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicant: CSL BEHRING RECOMBINANT FACILITY AG
    Inventors: Arna ANDREWS, Con PANOUSIS, Kerstin EMMRICH, Michael WILSON, Steve DOWER, Matthew HARDY, Dallas HARTMAN
  • MODIFIED VON WILLEBRAND FACTOR
    Publication number: 20170152300
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the modified polypeptide binds to Factor VIII with an off rate at least 5 fold lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Application
    Filed: July 2, 2015
    Publication date: June 1, 2017
    Applicant: CSL Limited
    Inventors: Michael WILSON, Steve DOWER, Dallas HARTMAN, Mathew HARDY